<DOC>
	<DOCNO>NCT01980875</DOCNO>
	<brief_summary>This study evaluate effect idelalisib obinutuzumab versus combination chlorambucil obinutuzumab progression-free survival ( PFS ) participants previously untreated chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Efficacy Safety Idelalisib Combination With Obinutuzumab Compared Chlorambucil Combination With Obinutuzumab Previously Untreated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>Not candidate fludarabine therapy base either : 1. creatinine clearance &lt; 70 mL/min , 2 . Cumulative Illness Rating Scale score &gt; 6 , assessment investigator Diagnosis Bcell CLL , diagnosis establish accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) No prior therapy CLL corticosteroid disease complication . CLL warrant treatment Presence measurable lymphadenopathy Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Known histological transformation CLL aggressive lymphoma ( ie , Richter transformation ) Known presence myelodysplastic syndrome Evidence ongoing systemic bacterial , fungal , viral infection time randomization Ongoing liver injury Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing immunosuppressive therapy corticosteroid Concurrent participation another therapeutic clinical trial Undergone major surgery within 30 day prior randomization Known hypersensitivity intolerance active substance excipients formulation IDELA , obinutuzumab , chlorambucil History noninfectious pneumonitis Received last dose study drug another therapeutic clinical trial within 30 day prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>